Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Nov;10(6):515-21.
doi: 10.1007/s11908-008-0083-y.

Strategies for promoting adherence to antiretroviral therapy: a review of the literature

Affiliations

Strategies for promoting adherence to antiretroviral therapy: a review of the literature

Jane M Simoni et al. Curr Infect Dis Rep. 2008 Nov.

Abstract

The success of antiretroviral therapy (ART) for HIV infection, though widespread and resounding, has been limited by inadequate adherence to its unforgiving regimens, especially over the long term. This article summarizes the literature on behavioral interventions to promote ART adherence and highlights some of the most recent and innovative research on patient education and case management, modified directly observed therapy, contingency management, interventions emphasizing social support, and novel technologies to promote awareness. Research in the area of adherence in pediatric HIV infection and in resource-constrained international settings also is considered. Although adherence interventions have been successful in experimental trials, they may not be feasible or adaptable given the constraints of real-world clinics and community-based settings. Implementation and dissemination of adherence interventions needs increased attention as ART adherence research moves beyond its first decade. We conclude with suggestions for incorporating research findings into clinical practice.

PubMed Disclaimer

Conflict of interest statement

Disclosures

No potential conflicts of interest relevant to this article were reported.

References

    1. Jones J, Taylor B, Wilkin TJ, Hammer S. Advances in antiretroviral therapy. Top HIV Med. 2007;15:48–82. Detailed summary of results from the 14th Conference on Retroviruses and Opportunistic Infections, which featured data on new antiretroviral agents, outcomes of antiretroviral therapy programs in resource-limited settings, and new information on mechanisms of drug resistance. - PubMed
    1. Crum NF, Riffenburgh RH, Wegner S, et al. Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras. J Acquir Immune Defic Syndr. 2006;41:194–200. - PubMed
    1. Shuter J. Forgiveness of non-adherence to HIV-1 antiretroviral therapy. J Antimicrob Chemother. 2008;61:769–773. - PubMed
    1. Giacca M. Gene therapy to induce cellular resistance to HIV-1 infection: lessons from clinical trials. Adv Pharmacol. 2008;56:297–325. - PubMed
    1. Perno CF, Moyle G, Tsoukas C, et al. Overcoming resistance to existing therapies in HIV-infected patients: the role of new antiretroviral drugs. J Med Virol. 2008;80:565–576. - PubMed